GLP-1 receptor agonist use and cancer risk in obese nondiabetic adults - PubMed
5 hours ago
- #obesity
- #GLP-1 receptor agonists
- #cancer risk
- GLP-1 receptor agonist (GLP-1RA) use in obese nondiabetic adults is associated with a significantly lower incidence of obesity-associated cancers (hazard ratio 0.59).
- The study, a target trial emulation using TriNetX data on 229,467 patients, compared GLP-1RA users to those receiving diet/exercise counseling after propensity score matching.
- Results showed reduced cancer risk in all subgroups except for black race, with consistent findings across sex, BMI categories, and specific drugs like semaglutide and tirzepatide.
- Prospective trials are needed to confirm causality, as this observational study suggests a potential protective effect of GLP-1RAs against cancer in obese individuals without diabetes.